Mast Cell Proteases Suppress Respiratory Viral Infections And Alleric Inflammation Of The Airways
Funder
National Health and Medical Research Council
Funding Amount
$665,532.00
Summary
Severe RSV infection and asthma accounts for poor quality of life in our community and current treatments have limited effects. Although the factors regulating these disorders are poorly understood, mast cells (MCs) may play important roles. We have shown MC protease-6 protects against viral infection. Here we will identify how MC and their factors are involved in the control of severe respiratory infections and allergic disease of the lung, and identify potential new ways to treat these conditi ....Severe RSV infection and asthma accounts for poor quality of life in our community and current treatments have limited effects. Although the factors regulating these disorders are poorly understood, mast cells (MCs) may play important roles. We have shown MC protease-6 protects against viral infection. Here we will identify how MC and their factors are involved in the control of severe respiratory infections and allergic disease of the lung, and identify potential new ways to treat these conditions.Read moreRead less
Predictors And Consequences Of Allergies That Impact On Children Getting A Healthy Start To Life:a Prospective Study
Funder
National Health and Medical Research Council
Funding Amount
$893,559.00
Summary
Allergic diseases prevent Australian children getting a healthy start to life by causing long term illnesses. This group of diseases includes asthma, hay fever, eczema and food allergies. Half of all Australian children are born into families with a history of these conditions and these children are at increased risk. Some of these children develop allergies while the others do not. It is also known that allergic conditions change over time, but we have no information on causes of these changes. ....Allergic diseases prevent Australian children getting a healthy start to life by causing long term illnesses. This group of diseases includes asthma, hay fever, eczema and food allergies. Half of all Australian children are born into families with a history of these conditions and these children are at increased risk. Some of these children develop allergies while the others do not. It is also known that allergic conditions change over time, but we have no information on causes of these changes. For example some infants with eczema continue to have eczema or develop hay fever and asthma, while others do not. The aim of this study is to determine what factors cause allergies and what factors influence these changes. This will provide evidence to guide health policy and clinical practice. Looking at the different conditions in family members over time is a good way to answer these types of questions, because parents and siblings share similar exposures, but not all the same genes. This helps to disentangle the effects of the environment and genes. The Melbourne Atopic Cohort Study (MACS) is amongst the world�s major studies on the development of allergies. MACS commenced in 1991-94 by recruiting 620 babies prior to birth. Only infants born into families with a history of allergic disease were included. MACS is unique because all family members and the home environment were assessed at the time of birth of the child. These children have been followed regularly over the first ten years of their life. The MACS now provides a unique opportunity to conduct a family study that can examine genes, childhood environment and individual risk factors for allergies. This will also allow exploration of the impact of allergies on families and the health care system, and how we can reduce that impact. Such information will provide evidence to guide health care policy and clinical practice. Also, the current study will provide a platform for future studies to investigate the progression of allergies in this family cohort. This will be the world's only longitudinal family follow-up of allergies that spans all of childhood. It will assist in reducing the impact of these common conditions, and the findings will be original and significant not only in Australia but also internationally.Read moreRead less
AusPollen: Implementation Of A Standardized National Pollen Alert System For Better Management Of Allergic Respiratory Health
Funder
National Health and Medical Research Council
Funding Amount
$626,442.00
Summary
In Australia, grass pollen is the main outdoor trigger for hay fever and allergic asthma. This AusPollen project will build and evaluate our first standardised pollen monitoring network. Pollen alerts and healthcare information will be delivered to patients and doctors via websites and Apps. The AusPollen program was initiated with The Australasian Society for Clinical Immunology and Allergy, Asthma Australia, Stallergenes, the Bureau of Meteorology CSIRO and MeteoSwiss.
Targeting MicroRNA (miRNA) As A Unified Therapeutic Approach To The Treatment Of Asthma And Allergic Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$675,030.00
Summary
Approximately 30% of our community suffers from allergic inflammation (asthma/rhinitis/dermatitis) that results in poor quality of life. The factors regulating these disorders are poorly understood and current treatments only target the symptoms and not the cause of disease. MicroRNA control gene expression and are emerging as potential regulators of inflammation. This project will identify the role of microRNA in the regulation of allergic diseases and their potential as new therapeutic targets ....Approximately 30% of our community suffers from allergic inflammation (asthma/rhinitis/dermatitis) that results in poor quality of life. The factors regulating these disorders are poorly understood and current treatments only target the symptoms and not the cause of disease. MicroRNA control gene expression and are emerging as potential regulators of inflammation. This project will identify the role of microRNA in the regulation of allergic diseases and their potential as new therapeutic targets.Read moreRead less
Harnessing Tyrosine Metabolism To Combat Respiratory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$866,467.00
Summary
Cross-talk between our immune system and the microbiome is central to health and disease. In particular, the gut microbiome has wide-ranging effects throughout the body, in part through the production of metabolites with immunomodulatory activity. We have discovered a novel subset of microbial metabolites which can protect mice against allergic airway inflammation, a model of asthma. We now aim to discovery how these metabolites work with a view towards developing them as therapeutics.
Determining The Role Of Vitamin D In The Development Of Asthma And Allergic Diseases In High Risk Families
Funder
National Health and Medical Research Council
Funding Amount
$351,127.00
Summary
Allergic diseases like asthma, eczema and hay-fever, prevent our children from getting a healthy start to life, and we don’t know how to prevent these conditions. Vitamin D levels may be critical in the development of childhood asthma and allergies, and they can be easily modified! Using a group of 620 children who we have followed for 20 years, we will identify the role of vitamin D levels in the development of allergic conditions, and factors that modify these relationships.
Evaluation Of The Safety Of Lead Compounds For Allergic Asthma
Funder
National Health and Medical Research Council
Funding Amount
$310,568.00
Summary
Asthma is one of the most common chronic respiratory diseases in developed countries and is typically treated with corticosteroids which provide symptomatic relief and coarse non-specific treatment of the underlying disease. We are pursuing innovative therapies by targeting a different enzyme, HPGD2S, involved in the inflammatory mechanisms of asthma. We have developed potent, anti-inflammatory drug candidates and aim to profile the safety of these compounds before entering clinical studies.
Disovery Of New Airway Epithelial Genes Regulating Allergic Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$446,934.00
Summary
Asthma is an inflammatory disease of the lungs that affects over 10% of all Australians. A number of drugs are currently available for the treatment of asthma, but there are many people whose asthma does not respond well to treatment. We have identified 2 genes, aP2 and mal1, that may be important in the development of asthma. Drugs targeted against these genes may be useful in the treatment of asthma. In this project, we aim to understand how aP2 and mal1 contribute to disease development.